Table 1. PBS-listed oral treatments for chronic hepatitis C .
| Daily drug regimen | Brand name | Genotype | Treatment duration (depending on patient characteristics) | |||
|---|---|---|---|---|---|---|
| No cirrhosis | Cirrhosis* | |||||
| Treatment-naïve | Treatment-experienced† | Treatment-naïve | Treatment-experience† | |||
| Sofosbuvir 400 mg/ledipasvir 90 mg fixed-dose combination | Harvoni | 1a or 1b | 8 weeks‡ or 12 weeks | 12 weeks | 12 weeks | 24 weeks |
| Sofosbuvir 400 mg + daclatasvir 60 mg (± ribavirin)§ | Sovaldi + Daklinza | 1a or 1b | 12 weeks | 12 weeks or 24 weeks | 12 weeks (+ ribavirin) or 24 weeks (no ribavirin) | 12 weeks (+ ribavirin) or 24 weeks (no ribavirin) |
| Paritaprevir 150 mg/ritonavir 100 mg/ ombitasvir 25 mg fixed-dose combination + dasabuvir 250 mg twice daily (± ribavirin)§ | Viekira Pak or Viekira Pak-RBV | 1a only | 12 weeks (+ ribavirin) | 12 weeks (+ ribavirin) | 12 weeks (+ ribavirin) | 12 weeks or 24 weeks (+ ribavirin) |
| 1b only | 12 weeks | 12 weeks | 12 weeks | 12 weeks | ||
| Elbasvir 50 mg/grazoprevir 100 mg fixed-dose combination (± ribavirin)§ | Zepatier | 1a or 1b, 4 | 12 weeks | 16 weeks (± ribavirin) | 12 weeks | 16 weeks (± ribavirin) |
| Sofosbuvir 400 mg + ribavirin§ | Sovaldi | 3 | 12 weeks | 12 weeks | 12 or 24 weeks (± ribavirin) | 12 or 24 weeks (± ribavirin) |
| Sofosbuvir 400 mg + daclatasvir 60 mg (± ribavirin)§ | Sovaldi + Daklinza | 2 | 12 weeks | 12 weeks | 12 weeks | 12 weeks |
| Sofosbuvir 400 mg/velpatasvir 100 mg fixed-dose combination# (± ribavirin)§ ¶ | Epclusa | 1–6 | 12 weeks | 12 weeks | 12 weeks | 12 weeks |
PBS Pharmaceutical Benefits Scheme
* Patients with cirrhosis should be managed in a specialist setting. An interferon-free regimen is not currently available for patients with genotype 6.
† Treatment-experienced usually refers to failure to clear virus on pegylated interferon plus ribavirin.
‡ Eight weeks may be considered if hepatitis C RNA is less than 6 × 106 IU/mL.
§ Ribavirin dosing is weight-based. Recommended dose is 1000 mg daily for people weighing less than 75 kg and 1200 mg daily for people weighing at least 75 kg.
# Currently (March 2017) recommended by the Pharmaceutical Benefits Advisory Committee for PBS listing.
¶ Adding ribavirin is recommended in all patients with decompensated cirrhosis and can be considered in patients with compensated cirrhosis who have genotype 3 infection.